SynthesisBMC cancer2025
Prognostic significance of cytogenetic and molecular features in pediatric acute myeloid leukemia: a meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPediatric acute myeloid leukemia (AML) is a clinically and genetically heterogeneous malignancy with variable outcomes. Accurate risk stratification based on cytogenetic and molecular markers is essential for guiding therapy. However, the prognostic impact of several key genomic alterations remains inconsistent across studies. This meta-analysis aims to evaluate the prognostic significance of cytogenetic and molecular abnormalities in pediatric AML and clarify their association with survival outcomes.
methodsA systematic search was conducted across PubMed, EMBASE, Scopus, Web of Science, and CENTRAL up to May 5, 2025. Studies were included if they reported survival outcomes in pediatric patients (≤ 18 years) with de novo AML and evaluated cytogenetic or molecular markers. Data were extracted and synthesized using a random-effects model. Hazard ratios (HRs) or risk ratios (RRs) were pooled for overall survival (OS), event-free survival (EFS), disease-free survival (DFS), complete remission (CR), and relapse risk (RR). Heterogeneity was assessed using I² statistics, and risk of bias was evaluated using the Newcastle-Ottawa Scale.
resultsThirty-nine studies encompassing over 1,645 pediatric patients were included in the meta-analysis. WT1 overexpression was significantly associated with OS (RR = 1.38, 95% CI: 1.17-1.63). KIT mutations were linked to inferior OS (RR = 0.69, 95% CI: 0.57-0.84), but not to CR, DFS, or relapse risk. FLT3-ITD mutations showed no consistent prognostic effect (RR = 0.97, 95% CI: 0.65-1.46), with substantial heterogeneity (I² = 83%). CEBPA mutations did not significantly impact EFS (RR = 1.00, 95% CI: 0.93-1.07), and neither RAS mutations nor EVI1 overexpression demonstrated prognostic relevance. Publication bias was minimal, and sensitivity analyses confirmed the robustness of pooled estimates.
conclusionWT1 overexpression and KIT mutations (in selected cytogenetic contexts) are validated as adverse prognostic indicators in pediatric AML. Conversely, FLT3-ITD and CEBPA mutations require nuanced interpretation due to variable effects and methodological heterogeneity. These findings support the integration of molecular profiling into pediatric AML risk stratification and underscore the need for harmonized, prospective studies to refine prognostic models in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.